Comment on Ethical Concerns Regarding Conbercept for Treatment of Neovascular Age-Related Macular Degeneration: Phase 3 PHOENIX Study

We read the article by Liu and associates1; however, we believe that some discussion is required. The authors present the results of conbercept (Lumitin, Chengdu Kanghong Biotech Co., PR of China) treatment of neovascular age-related macular degeneration (AMD).

Source: American Journal of Ophthalmology - November 5, 2019 Category: Opthalmology Authors: Andrzej Grzybowski, Piotr Kanclerz Tags: Correspondence Source Type: research